A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from ...

A community bowling fundraiser is raising money to help a local man cover cancer treatment and travel expenses.

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration.

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations.

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...